You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTetrabenazine
Accession NumberDB04844
TypeSmall Molecule
GroupsApproved
DescriptionA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Structure
Thumb
Synonyms
1,2,4,6,7,11b-hexahydro-3-Isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one
2-oxo-3-Isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bh-benzo[a]quinolizine
2-oxo-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-benzoquinolizine
TBZ
Tetra benazin
Tetrabenazina
Tetrabenazinum
Tetrabenzaine
Tetrabenzine
External Identifiers
  • Ro 1-9569
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NitomanTablet25 mgOralValeant Canada Lp Valeant Canada S.E.C.1996-12-09Not applicableCanada
PMS-tetrabenazineTablet25 mgOralPharmascience Inc2013-02-26Not applicableCanada
TetrabenazineTablet12.5 mg/1OralOceanside Pharmaceuticals2015-07-20Not applicableUs
TetrabenazineTablet25 mg/1OralOceanside Pharmaceuticals2015-07-20Not applicableUs
Tetrabenazine TabletsTablet25 mgOralSterimax Inc2013-08-29Not applicableCanada
XenazineTablet12.5 mg/1OralLundbeck Inc.2008-11-24Not applicableUs
XenazineTablet25 mg/1OralLundbeck Inc.2008-11-24Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tetrabenazineTablet25 mgOralApotex Inc2013-11-01Not applicableCanada
TetrabenazineTablet, coated12.5 mg/1OralCamber Pharmaceuticals, Inc.2015-08-17Not applicableUs
TetrabenazineTablet, coated25 mg/1OralCamber Pharmaceuticals, Inc.2015-08-17Not applicableUs
TetrabenazineTablet25 mg/1OralSun Pharma Global FZE2015-08-17Not applicableUs
TetrabenazineTablet12.5 mg/1OralSun Pharma Global FZE2015-08-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RubigenNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIZ9O08YRN8O
CAS number58-46-8
WeightAverage: 317.4226
Monoisotopic: 317.199093735
Chemical FormulaC19H27NO3
InChI KeyMKJIEFSOBYUXJB-UHFFFAOYSA-N
InChI
InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3
IUPAC Name
9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one
SMILES
COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1
Pharmacology
IndicationTreatment of hyperkinetic movement disorders like chorea in Huntington's disease, hemiballismus, senile chorea, Tourette syndrome and other tic disorders, and tardive dyskinesia
Structured Indications
PharmacodynamicsProlongation of the QTc interval has been observed at doses of 50 mg. In rats, it has been observed that tetrabenazine or its metabolites bind to melanin-containing tissues such as the eyes and skin. After a single oral dose of radiolabeled tetrabenazine, radioactivity was still detected in eye and fur at 21 days post dosing.
Mechanism of actionTetrabenazine is a reversible human vesicular monoamine transporter type 2 inhibitor (Ki = 100 nM). It acts within the basal ganglia and promotes depletion of monoamine neurotransmitters serotonin, norepinephrine, and dopamine from stores. It also decreases uptake into synaptic vesicles. Dopamine is required for fine motor movement, so the inhibition of its transmission is efficacious for hyperkinetic movement. Tetrabenazine exhibits weak in vitro binding affinity at the dopamine D2 receptor (Ki = 2100 nM).
TargetKindPharmacological actionActionsOrganismUniProt ID
Synaptic vesicular amine transporterProteinyes
inhibitor
HumanQ05940 details
D(2) dopamine receptorProteinunknown
inhibitor
HumanP14416 details
Related Articles
AbsorptionFollowing oral administration of tetrabenazine, the extent of absorption is at least 75%. After single oral doses ranging from 12.5 to 50 mg, plasma concentrations of tetrabenazine are generally below the limit of detection because of the rapid and extensive hepatic metabolism of tetrabenazine. Food does not affect the absorption of tetrabenazine. Cmax, oral = 4.8 ng/mL in HD or tardive dyskinesia patients; Tmax, oral = 69 min in HD or tardive dyskinesia patients
Volume of distribution

Steady State, IV, in HD or tardive dyskinesia patients: 385L.
Tetrabenazine is rapidly distributed to the brain following IV injection. The site with the highest binding is the striatum, while the lowest binding was observed in the cortex.

Protein bindingTetrabenazine = 82 - 88%; α-HTBZ = 60 - 68%; β-HTBZ = 59 - 63%.
Metabolism

Tetrabenazine is hepatically metabolized. Carbonyl reductase in the liver is responsible for the formation of two major active metabolites: α-dihydrotetrabenazine (α-HTBZ) and β-dihydrotetrabenazine (β-HTBZ). α-HTBZ is further metabolized into 9-desmethyl-α-DHTBZ, a minor metabolite by CYP2D6 and with some contribution of CYP1A2. β-HTBZ is metabolized to another major circulating metabolite, 9-desmethyl-β-DHTBZ, by CYP2D6. The Tmax of this metabolite is 2 hours post-administration of tetrabenazine.

SubstrateEnzymesProduct
Tetrabenazine
alpha-dihydrotetrabenazineDetails
Tetrabenazine
Not Available
b-dihydrotetrabenazineDetails
Route of eliminationAfter oral administration, tetrabenazine is extensively hepatically metabolized, and the metabolites are primarily renally eliminated (75%). Tetrabenazine is also cleared fecally (7% to 16%). Unchanged tetrabenazine has not been found in human urine. Urinary excretion of α-HTBZ or β-HTBZ (the major metabolites) accounted for less than 10% of the administered dose.
Half lifeα-HTBZ = 7 hours; β-HTBZ = 5 hours; 9-desmethyl-β-DHTBZ = 12 hours.
Clearance

IV, 1.67 L/min in HD or tardive dyskinesia patients

ToxicityDose-limiting adverse effects are sedation, parkinsonism, akathsia, and depression. LD50 oral, mouse: 550 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetrabenazine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Tetrabenazine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Acetophenazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Tetrabenazine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetrabenazine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tetrabenazine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tetrabenazine.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tetrabenazine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetrabenazine.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Tetrabenazine.Approved
AmiodaroneThe serum concentration of Tetrabenazine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Tetrabenazine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetrabenazine.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Tetrabenazine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Amperozide.Experimental
AnagrelideAnagrelide may increase the QTc-prolonging activities of Tetrabenazine.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aripiprazole.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
ArtemetherTetrabenazine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tetrabenazine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Tetrabenazine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Azaperone.Vet Approved
AzelastineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tetrabenazine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Tetrabenazine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tetrabenazine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrabenazine.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Tetrabenazine.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tetrabenazine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tetrabenazine.Approved
BetaxololThe metabolism of Tetrabenazine can be decreased when combined with Betaxolol.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Bifeprunox.Investigational
BortezomibBortezomib may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tetrabenazine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrabenazine.Approved, Illicit
BromperidolThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tetrabenazine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tetrabenazine.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetrabenazine.Approved, Investigational
BuprenorphineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Tetrabenazine can be increased when it is combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Tetrabenazine.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrabenazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrabenazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tetrabenazine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tetrabenazine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tetrabenazine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tetrabenazine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrabenazine.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetrabenazine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tetrabenazine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tetrabenazine.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetrabenazine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Caroxazone.Withdrawn
CelecoxibThe metabolism of Tetrabenazine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibCeritinib may increase the QTc-prolonging activities of Tetrabenazine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tetrabenazine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetrabenazine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetrabenazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tetrabenazine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetrabenazine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tetrabenazine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tetrabenazine.Approved
CholecalciferolThe metabolism of Tetrabenazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Tetrabenazine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Tetrabenazine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetrabenazine.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Tetrabenazine.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Tetrabenazine.Approved
ClemastineThe metabolism of Tetrabenazine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Tetrabenazine.Approved
ClobazamThe metabolism of Tetrabenazine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tetrabenazine.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Tetrabenazine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tetrabenazine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrabenazine.Approved, Illicit
ClotrimazoleThe metabolism of Tetrabenazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Clozapine.Approved
CobicistatThe serum concentration of Tetrabenazine can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Tetrabenazine can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrabenazine.Approved, Illicit
CrizotinibCrizotinib may increase the QTc-prolonging activities of Tetrabenazine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Tetrabenazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrabenazine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tetrabenazine.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Tetrabenazine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tetrabenazine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Tetrabenazine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Tetrabenazine can be increased when it is combined with Darunavir.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Tetrabenazine.Approved
DelavirdineThe serum concentration of Tetrabenazine can be increased when it is combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Tetrabenazine.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Tetrabenazine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Tetrabenazine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tetrabenazine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tetrabenazine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrabenazine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetrabenazine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetrabenazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetrabenazine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tetrabenazine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tetrabenazine.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Tetrabenazine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrabenazine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetrabenazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrabenazine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tetrabenazine.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Tetrabenazine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetrabenazine.Approved, Illicit
DisopyramideDisopyramide may increase the QTc-prolonging activities of Tetrabenazine.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Tetrabenazine.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Tetrabenazine.Approved
DomperidoneDomperidone may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tetrabenazine.Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Tetrabenazine.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tetrabenazine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved, Illicit
DronedaroneTetrabenazine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tetrabenazine.Experimental, Illicit
DuloxetineThe metabolism of Tetrabenazine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrabenazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tetrabenazine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Tetrabenazine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tetrabenazine.Approved, Investigational
EliglustatTetrabenazine may increase the QTc-prolonging activities of Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tetrabenazine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tetrabenazine.Approved, Investigational
EribulinEribulin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tetrabenazine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetrabenazine.Approved
EthanolTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrabenazine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tetrabenazine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tetrabenazine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrabenazine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetrabenazine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetrabenazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tetrabenazine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tetrabenazine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tetrabenazine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrabenazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tetrabenazine.Illicit, Vet Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Tetrabenazine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Tetrabenazine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Tetrabenazine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrabenazine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Tetrabenazine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Tetrabenazine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Flibanserin.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Tetrabenazine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrabenazine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tetrabenazine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tetrabenazine.Approved, Illicit
FluoxetineThe serum concentration of Tetrabenazine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrabenazine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tetrabenazine.Approved
FluvoxamineThe metabolism of Tetrabenazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Tetrabenazine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Tetrabenazine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tetrabenazine.Approved, Illicit
FurazolidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Furazolidone.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrabenazine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with gabapentin enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Tetrabenazine.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Tetrabenazine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tetrabenazine.Approved, Illicit
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tetrabenazine.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Tetrabenazine.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tetrabenazine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tetrabenazine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tetrabenazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tetrabenazine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetrabenazine.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Tetrabenazine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Hydracarbazine.Approved
HydrocodoneTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrabenazine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Tetrabenazine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Iloperidone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Tetrabenazine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Tetrabenazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Tetrabenazine.Approved
IndinavirThe metabolism of Tetrabenazine can be decreased when combined with Indinavir.Approved
IproclozideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Isocarboxazid.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Tetrabenazine.Approved, Vet Approved
IsoniazidThe metabolism of Tetrabenazine can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Tetrabenazine.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Tetrabenazine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrabenazine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetrabenazine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tetrabenazine.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrabenazine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Tetrabenazine.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tetrabenazine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tetrabenazine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Tetrabenazine.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetrabenazine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetrabenazine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tetrabenazine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tetrabenazine.Illicit
LopinavirThe serum concentration of Tetrabenazine can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tetrabenazine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrabenazine.Approved
LorcaserinThe metabolism of Tetrabenazine can be decreased when combined with Lorcaserin.Approved
LoxapineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Tetrabenazine.Investigational
LumefantrineTetrabenazine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved, Vet Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Tetrabenazine.Approved
MebanazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Mebanazine.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Tetrabenazine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tetrabenazine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Tetrabenazine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tetrabenazine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrabenazine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrabenazine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetrabenazine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Tetrabenazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tetrabenazine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetrabenazine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tetrabenazine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetrabenazine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetrabenazine.Approved
MethotrimeprazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetrabenazine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methsuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetrabenazine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrabenazine.Approved, Investigational
MetoprololThe metabolism of Tetrabenazine can be decreased when combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Tetrabenazine.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Tetrabenazine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrabenazine.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Tetrabenazine.Approved
MirtazapineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Moclobemide.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Tetrabenazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrabenazine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetrabenazine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Nefazodone.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Tetrabenazine.Approved
NevirapineThe metabolism of Tetrabenazine can be decreased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Nialamide.Withdrawn
NicardipineNicardipine may increase the QTc-prolonging activities of Tetrabenazine.Approved
NilotinibTetrabenazine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetrabenazine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tetrabenazine.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tetrabenazine.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Tetrabenazine.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Octamoxin.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Olanzapine.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Tetrabenazine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetrabenazine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tetrabenazine.Approved, Illicit
OrphenadrineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetrabenazine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrabenazine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tetrabenazine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrabenazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetrabenazine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Tetrabenazine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pargyline.Approved
ParoxetineThe serum concentration of Tetrabenazine can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Tetrabenazine.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Tetrabenazine.Approved
Peginterferon alfa-2bThe serum concentration of Tetrabenazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Tetrabenazine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrabenazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetrabenazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Tetrabenazine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetrabenazine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Phenelzine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetrabenazine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tetrabenazine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Phenoxypropazine.Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tetrabenazine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pomalidomide.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational, Vet Approved
PramipexoleTetrabenazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tetrabenazine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetrabenazine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tetrabenazine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tetrabenazine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Tetrabenazine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Tetrabenazine.Approved, Vet Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Tetrabenazine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tetrabenazine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Tetrabenazine.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Tetrabenazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetrabenazine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Propericiazine.Approved
PropofolPropofol may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tetrabenazine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Tetrabenazine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tetrabenazine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetrabenazine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Quetiapine.Approved
QuinidineThe serum concentration of Tetrabenazine can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the QTc-prolonging activities of Tetrabenazine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrabenazine.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrabenazine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrabenazine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Tetrabenazine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Tetrabenazine can be increased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Tetrabenazine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tetrabenazine.Vet Approved
RopiniroleTetrabenazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrabenazine.Approved
RotigotineTetrabenazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tetrabenazine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tetrabenazine.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Tetrabenazine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Tetrabenazine.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tetrabenazine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrabenazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Tetrabenazine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Tetrabenazine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Tetrabenazine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Tetrabenazine.Approved
StiripentolThe serum concentration of Tetrabenazine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrabenazine.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Tetrabenazine.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Tetrabenazine.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sulpiride.Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
SuvorexantTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenTamoxifen may increase the QTc-prolonging activities of Tetrabenazine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tasimelteon.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Tetrabenazine.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Tetrabenazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetrabenazine.Approved
TerbinafineThe serum concentration of Tetrabenazine can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tetrabenazine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tetrabenazine.Investigational
ThalidomideTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetrabenazine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetrabenazine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Tetrabenazine can be increased when it is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tetrabenazine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Tetrabenazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tetrabenazine.Vet Approved
TipranavirThe serum concentration of Tetrabenazine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tetrabenazine.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Toloxatone.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tetrabenazine.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrabenazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetrabenazine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Tetrabenazine.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tetrabenazine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Vet Approved
Uc1010The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tetrabenazine.Approved, Investigational
VandetanibTetrabenazine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Tetrabenazine.Approved
VemurafenibTetrabenazine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Tetrabenazine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Tetrabenazine.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Tetrabenazine.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tetrabenazine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tetrabenazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrabenazine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tetrabenazine.Vet Approved
ZolpidemTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tetrabenazine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tetrabenazine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Michael James Rishel, Kande Kankananamalage Dayarathna Amarasinghe, Sean Richard Dinn, Bruce Fletcher Johnson, “METHOD FOR MAKING TETRABENAZINE COMPOUNDS.” U.S. Patent US20080306267, issued December 11, 2008.

US20080306267
General References
  1. Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb;48(2):358-62. [PubMed:9040721 ]
  2. Guay DR: Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010 Aug;8(4):331-73. doi: 10.1016/j.amjopharm.2010.08.006. [PubMed:20869622 ]
External Links
ATC CodesN07XX06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (269 KB)
MSDSDownload (79.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9639
Caco-2 permeable+0.8608
P-glycoprotein substrateSubstrate0.7819
P-glycoprotein inhibitor IInhibitor0.8908
P-glycoprotein inhibitor IIInhibitor0.7631
Renal organic cation transporterInhibitor0.6484
CYP450 2C9 substrateNon-substrate0.8444
CYP450 2D6 substrateSubstrate0.6448
CYP450 3A4 substrateSubstrate0.8091
CYP450 1A2 substrateNon-inhibitor0.7482
CYP450 2C9 inhibitorNon-inhibitor0.9042
CYP450 2D6 inhibitorInhibitor0.7084
CYP450 2C19 inhibitorNon-inhibitor0.8191
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8718
Ames testNon AMES toxic0.6674
CarcinogenicityNon-carcinogens0.9083
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.8540 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6451
hERG inhibition (predictor II)Inhibitor0.7524
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg
TabletOral12.5 mg/1
TabletOral25 mg/1
Tablet, coatedOral12.5 mg/1
Tablet, coatedOral25 mg/1
Prices
Unit descriptionCostUnit
Xenazine 25 mg tablet74.57USD tablet
Xenazine 12.5 mg tablet37.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point126 °CMSDS
water solubilitySparingly solubleFDA label
pKa6.51FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.361 mg/mLALOGPS
logP3.23ALOGPS
logP3.4ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)18.24ChemAxon
pKa (Strongest Basic)7.41ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity91.31 m3·mol-1ChemAxon
Polarizability36.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassTetrahydroisoquinolines
Sub ClassNot Available
Direct ParentTetrahydroisoquinolines
Alternative Parents
Substituents
  • Tetrahydroisoquinoline
  • Anisole
  • Aralkylamine
  • Piperidinone
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Cyclic ketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene Name:
SLC18A2
Uniprot ID:
Q05940
Molecular Weight:
55712.075 Da
References
  1. Zheng G, Dwoskin LP, Crooks PA: Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 2006 Nov 10;8(4):E682-92. [PubMed:17233532 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Kim YS, Shin JH, Hall FS, Linden DJ: Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8. doi: 10.1523/JNEUROSCI.0468-09.2009. [PubMed:19571144 ]
  4. Goland R, Freeby M, Parsey R, Saisho Y, Kumar D, Simpson N, Hirsch J, Prince M, Maffei A, Mann JJ, Butler PC, Van Heertum R, Leibel RL, Ichise M, Harris PE: 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med. 2009 Mar;50(3):382-9. doi: 10.2967/jnumed.108.054866. Epub 2009 Feb 17. [PubMed:19223416 ]
  5. Gros Y, Schuldiner S: Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter. J Biol Chem. 2010 Feb 12;285(7):5076-84. doi: 10.1074/jbc.M109.081216. Epub 2009 Dec 10. [PubMed:20007701 ]
  6. Wimalasena K: Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev. 2011 Jul;31(4):483-519. doi: 10.1002/med.20187. Epub 2010 Feb 4. [PubMed:20135628 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Poon LH, Kang GA, Lee AJ: Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother. 2010 Jun;44(6):1080-9. doi: 10.1345/aph.1M582. Epub 2010 May 4. [PubMed:20442355 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-e2 9-reductase activity
Specific Function:
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alp...
Gene Name:
CBR1
Uniprot ID:
P16152
Molecular Weight:
30374.73 Da
References
  1. Jankovic J, Clarence-Smith K: Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011 Nov;11(11):1509-23. doi: 10.1586/ern.11.149. [PubMed:22014129 ]
Comments
comments powered by Disqus
Drug created on October 16, 2007 11:37 / Updated on August 17, 2016 12:24